Altered Fat Distribution in HIV-Positive Men on Nucleoside Analog Reverse Transcriptase Inhibitor Therapy

This publication has 19 references indexed in Scilit:

• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
  AIDS, 2000
• A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
  AIDS, 2000
• Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study
  AIDS, 2000
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
  The Lancet, 1999
• A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
  AIDS, 1999
• Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
  AIDS, 1999
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
  The Lancet, 1998
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
  AIDS, 1998
• Visceral abdominal-fat accumulation associated with use of indinavir
  The Lancet, 1998
• “Buffalo hump” in men with HIV-1 infection
  The Lancet, 1998